Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
2.620
+0.120 (4.80%)
Sep 2, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Revenue
In the year 2025, Serina Therapeutics had annual revenue of $130.00K with 132.14% growth.
Revenue (ttm)
$130.00K
Revenue Growth
+132.14%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
66.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.00K | 74.00K | 132.14% |
| Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
| Dec 31, 2023 | 3.15M | 3.12M | 9,173.53% |
| Dec 31, 2022 | 34.00K | -110.00K | -76.39% |
| Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
| Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
| Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
| Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
| Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| MindWalk Holdings | 11.43M |
| Alps Group | 3.74M |
| iBio, Inc. | 100.00K |
| INmune Bio | 50.00K |
| eXoZymes | -700.00 |
SER News
- 9 days ago - Serina Therapeutics files to sell 12.5M shares of common stock for holders - TheFly
- 9 days ago - Serina Therapeutics Registration statement: Registration filing - Filings
- 20 days ago - Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 20 days ago - Serina Therapeutics Quarterly report: Q2 2026 - Filings
- 20 days ago - Serina Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics completes enrollment and dosing in Parkinson’s trial - TheFly
- 5 weeks ago - Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire